Despite this, the evidence previously presented shows that there is a subgroup of patients who benefit mostly from adjuvant therapies in PCa with BCR, while others, who have lower risk, may be subjected to unnecessary treatment. The gene discussed is BCR; the disease is posterior cortical atrophy.